Evidence map›Paper›PMID 39698396›Full record

ArticleToxicology research2024

Microrna-342 inhibits hepatocellular carcinoma cell proliferation and promotes apoptosis through the FOXP1/MYCBP Signaling Axis.

Yanling Zhang, Guang Da Yang, Qian Ya Chen, Jinlong Zeng, Yang Cao

Abstract read
In one paragraph

Article in Toxicology research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yanling ZhangDepartment of Oncology, The Fourth Affiliated Hospital of Guangzhou Medical University, No. 232, Outer Ring East Road, Panyu District, Guangzhou 510000 Guangdong Province, China.ORCID https://orcid.org/0009-0002-2184-0693
Guang Da YangDepartment of Oncology, The Fourth Affiliated Hospital of Guangzhou Medical University, No. 232, Outer Ring East Road, Panyu District, Guangzhou 510000 Guangdong Province, China.
Qian Ya ChenDepartment of Oncology, The Fourth Affiliated Hospital of Guangzhou Medical University, No. 232, Outer Ring East Road, Panyu District, Guangzhou 510000 Guangdong Province, China.
Jinlong ZengDepartment of Oncology, The Fourth Affiliated Hospital of Guangzhou Medical University, No. 232, Outer Ring East Road, Panyu District, Guangzhou 510000 Guangdong Province, China.
Yang CaoDepartment of Oncology, The Fourth Affiliated Hospital of Guangzhou Medical University, No. 232, Outer Ring East Road, Panyu District, Guangzhou 510000 Guangdong Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To investigate the role and mechanism of miR-342 and FOXP1 on hepatocellular carcinoma cells. QRT-PCR was applied to determine the expression of miR-342, FOXP1 and MYCBP in normal hepatocyte cell lines (NHC), hepatocellular carcinoma cell lines (HEK-293 T) and human hepatocellular carcinoma cell lines (HepG2, MHCC97-L, Huh7 and SMMC7721). After knockdown or over-expression of miR-342 and FOXP1 in HepG2 cells respectively, cell proliferation and cell viability were measured using MTT assay and colony formation assay. Flow cytometry was adopted to test for apoptosis. Dual luciferase gene reporter assays were performed to validate the target relationship between FOXP1and miR-342 or MYCBP. The level of apoptosis-related proteins cleaved-caspase-3, Bcl-2 and Bax were measured by western blot. Compared with NHC, miR-342 expression was decreased and FOXP1 expression was up-regulated in hepatocellular carcinoma cell lines. MiR-342 could target and negatively regulate FOXP1. FOXP1 could promote the proliferation of hepatocellular carcinoma cells, positively regulate the expression of c-Caspase-3, Bax, negatively regulate Bcl-2 and inhibit apoptosis. FOXP1 can also target and positively regulate MYCBP. The expression of MYCBP was up-regulated in the hepatocellular carcinoma cell lines, while overexpression of miR-342 decreased MYCBP expression promoted by overexpression of FOXP1. MiR-342 can inhibit FOXP1/MYCBP signaling axis to regulate the members of Caspase-3 and Bcl-2 family to inhibit the proliferation and promote apoptosis of hepatocellular carcinoma cells.

Indexed as

ApoptosisFOXP1/MYCBP signaling axisHepatocellular carcinomamiR-342Proliferation

Identifiers

PMID39698396
PMCPMC11649998

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.